# Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment

> **NCT03637400** · PHASE2 · COMPLETED · sponsor: **Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center** · enrollment: 269 (actual)

## Conditions studied

- Methicillin-resistant Staphylococcus Aureus
- Skin Infection

## Interventions

- **DRUG:** TMP-SMX
- **DRUG:** DOXY

## Key facts

- **NCT ID:** NCT03637400
- **Lead sponsor:** Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-26
- **Primary completion:** 2024-02-12
- **Final completion:** 2025-06-30
- **Target enrollment:** 269 (ACTUAL)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03637400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03637400, "Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03637400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*